48
Views
0
CrossRef citations to date
0
Altmetric
Drug Profile

Pharmacoeconomics and quality of life analysis of telmisartan in hypertension treatment

&
Pages 435-444 | Published online: 09 Jan 2014

References

  • Murray CJ, Lopez AD. Evidence-based health policy: lessons from the Global Burden of Disease Study. Science274, 740–743 (1996).
  • Dustan HP, Roccella EJ, Garrison HH. Controlling hypertension. A research success story. Arch. Intern. Med.156, 1926–1935 (1996).
  • Chobanian AV, Bakris GL, Black HR et al.; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA289, 2560–2572 (2003).
  • Singh RB, Suh IL, Singh VP et al. Hypertension and stroke in Asia: prevalence, control and strategies in developing countries for prevention. Hum. Hypertens.14, 749–763 (2000).
  • Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases. Part I: General considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation104, 2746–2753 (2001).
  • Brown CD, Higgins M, Donato KA et al. Body mass index and the prevalence of hypertension and dyslipidemia. Obes. Res.8, 605–619 (2000).
  • Cupples LA, D’Agostino RB, Kiely D. The Framingham Study. An Epidemiological Investigation of Cardiovascular Disease, Section 34. Some of the risk factors related to the annual incidence of cardiovascular disease and death using pooled repeated biennial measurements: Framingham Heart Study, 30-year follow-up. National Heart, Lung and Blood Institute MD, USA (1987).
  • Klungel OH, Stricker BH, Paes AH et al. Excess stroke among hypertensive men and women attributable to undertreatment of hypertension. Stroke30, 1312–1318 (1999).
  • Redon J. The normal circadian pattern of blood pressure: implications for treatment. Int. J. Clin. Pract.58(Suppl. 145), 3–8 (2004).
  • Weber MA. The 24-hour blood pressure pattern: does it have implications for morbidity and mortality? Am. J. Cardiol.89(Suppl. 2A), 27–33A (2002).
  • Dzau V. The cardiovascular continuum and renin–angiotensin–aldosterone system blockade. J. Hypertens.23(Suppl. 1), S9–S17 (2005).
  • Chrysant SG, Chrysant GS, Desai A. Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan. J. Hum. Hypertens.19(3), 173–183 (2005).
  • Bakris GL, Mensah GA. Pathogenesis and clinical physiology of hypertension. Cardiol. Clin.20(2), 195–206 (2002).
  • Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs61(10), 1501–1529 (2001).
  • Clark R. Drug review – telmisartan. Drugs in Context Primary Care Part B: Cardiovascular Medicine II1(6), 229–246 (2004).
  • Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020, Global Burden of Disease Study. Lancet349, 1498–1504 (1997).
  • American Heart Association. 2002 Heart and Stroke Statistical Update. American Heart Association TX, USA (2001).
  • Rosamond W, Flegal K, Friday G et al; Heart disease and stroke statistics – 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation115(5), 69–171 (2007).
  • Petersen S, Peto V, Rayner M, Leal J, Luengo-Fernandez R, Gray A. European Cardiovascular Disease Statistics. Joint publication by the British Heart Foundation, European Heart Network and the Health Economics Research Centre at the University of Oxford, Oxford, UK (2005).
  • Leal J, Luengo-Fernandez R, Gray A et al. Economic burden of cardiovascular diseases in the enlarged European Union. Eur. Heart J.27, 1610–1619 (2006).
  • Khan JM, Beevers DG. Management of hypertension in ethnic minorites. Heart91(8), 1105–1109 (2005).
  • Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin. Ther.19, 1446–1457 (1997).
  • Hughes D, McGuire A. The direct costs to the NHS of discontinuing and switching prescriptions for hypertension. J. Hum. Hypertens.12, 533–537 (1998).
  • Kirch W, Horn B, Schweizer J. Comparison of angiotensin II receptor antagonists. Eur. J. Clin. Invest.31(8), 698–706 (2001).
  • Burnier M, Maillard M. The comparative pharmacology of angiotensin II receptor antagonists. Blood Press.10(Suppl.), 6–11 (2001).
  • Scheen AJ. Renin–angiotensin system inhibition prevents Type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab.30(6) 487–496 (2004).
  • Abuissa H, Jones PG, Marso SP et al. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of Type 2 diabetes: a meta-analysis of randomized clinical trials. J. Am. Coll. Cardiol.46(5), 821–826 (2005).
  • Gillespie EL, White CM, Kardas M et al. The impact of ACE inhibitors or angiotensin II Type 1 receptor blockers on the development of new-onset Type 2 diabetes. Diabetes Care28(9), 2261–2266 (2005).
  • Schrader J, Lüders S, Kulschewski A et al.; for the MOSES Study Group. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke36, 1218–1226 (2005).
  • Lithell H, Hansson L, Skoog I et al.; for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. J. Hypertens.21, 875–886 (2003).
  • Schrader J, Lüders S, Kulschewski A et al. on behalf of the ACCESS Study Group. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke34, 1699–1703 (2003).
  • Bloch MJ, Basile J. Defining the role of angiotensin receptor blocker therapy in Japanese persons with underlying vascular disease: the Jikei Heart Study. J. Clin. Hypertens.9(7), 576–579 (2007).
  • Fukui T, Rahman M, Morita S, Sakamoto J. Informed consent in the Candesartan Anthiypertensive Survival Evaluation in Japan (CASE-J) trial: a survey of collaborating physicians. Hypertens. Res.29(7), 471–474 (2006).
  • Dahlöf B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet359, 995–1003 (2002).
  • Dahlof B, Devereux R, de Faire U et al. The Losartan Intervention For Endpoint reduction (LIFE) in hypertension study: rationale, design, and methods. The LIFE Study Group. Am. J. Hypertens.10, 705–713 (1997).
  • Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet363, 2022–2031 (2004).
  • Weber MA, Julius S, Kjeldsen SE et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet363, 2049–2051 (2004).
  • Teo K, Yusuf S, Sleight P et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/ Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/ TRANSCEND) trials. Am. Heart J.148, 52–61 (2004).
  • de Gasparo M. AT1 receptor antagonists: pharmacology. In: Part 5. Inhibition of the Renin-Angiotensin System. Angiotensin – Vol. II. Series: Handbook of Experimental Pharmacology (Vol. 163) Unger T, Schölkens BA (Eds). Springer Verlag, Heidelberg, Germany 417–452 (2004).
  • Kakuta H, Sudoh K, Sasamata M et al. Telmisartan has the strongest binding affinity to angiotensin II type I receptor: comparison with other angiotensin II type 1 receptor blockers. Int. J. Clin. Pharmacol. Res.25(1), 41–46 (2005).
  • Maillard MP, Perregaux C, Centeno C et al.In vitro and in vivo characterization of the activity of telmisartan : an insurmountable angiotensin II receptor antagonist. J. Pharmacol. Exp. Ther.302(3), 1089–1095 (2002).
  • Stangier J, Su C-APF, van Heiningen PNM et al. Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge. J. Cardiovasc. Pharmacol.38(5), 672–685 (2001).
  • Karlberg BE, Lins LE, Hermansson K. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. J. Hypertens.17(2), 293–302 (1999).
  • Smith DH, Matzek KM. Kempthorne-Rawson J. Dose response and safety of telmisartan in patients with mild to moderate hypertension. J. Clin. Pharmacol.40(12 Pt 1), 1380–1390 (2000).
  • Schupp M, Janke J, Clasen R et al. Angiotensin Type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation109(17), 2054–2057 (2004).
  • Benson SC, Pershadsingh HA, Ho CI et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-γ-modulating activity. Hypertension43(5), 993–1002 (2004).
  • Fujimoto M, Masuzaki H, Tanaka T et al. An angiotensin II AT1 receptor antagonist, telmisartan, augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett.576(3), 492–497 (2004).
  • Fogari R, Lazzari P, Zoppi A et al. Effect of telmisartan, losartan, and lisinopril on insulin sensitivity in hypertensive patients with and without insulin resistance. Eur. Heart J.25, 78 (2004) (Abstract P525).
  • Battershill AJ, Scott LJ. Telmisartan – a review of its use in the management of hypertension. Drugs66(1), 52–83 (2006).
  • Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J. Hum. Hypertens.14(Suppl. 1), S73–S86 (2000).
  • Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet355(9204), 637–645 (2000).
  • Hasford J. Compliance and benefit/risk relationship of antihypertensive treament. J. Cardiovasc. Pharmacol.20(Suppl. 6), S30–S34 (1992).
  • Mancia G, Lanfranchi A, Cattaneo BM, Grassi G. Hypertension – when is the clinical problem solved? When patients are rendered normotensive. Cardiology85(Suppl. 1), 58–64 (1994).
  • Li W, Liu L, Puente JG et al. Hypertension and health-related quality of life: an epidemiological study in patients attending hospital clinics in China. J. Hypertens.23, 1667–1676 (2005).
  • Stewart AL, Greenfield S, Hays RD et al. Functional status and well-being of patients with chronic conditions. JAMA269, 907–913 (1989).
  • Bulpitt CJ, Dollery CT, Carne S. Change in symptoms of hypertensive patients after referral to hospital clinic. Br. Heart J.38, 121–128 (1976).
  • Kjellgren K, Ahlner J, Dahlof B et al. Perceived symptoms amongst hypertensive patients in routine clinical practice – a population-based study. J. Intern. Med.244, 325–332 (1998).
  • Moller L, Kristensen TS, Hollnagel H. Self rated health as a predictor of coronary heart disease in Copenhagen, Denmark. J. Epidemiol. Community Health50, 423–428 (1996).
  • Kottke T, Tuomiletho J, Puska P et al. The relationship of symptoms and blood pressure in a population sample. Int. J. Epidemiol.8, 355–359 (1979).
  • Weber MA, Bakris GL, Neutel JM et al. Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker. J. Clin. Hypertens.5(5), 322–329 (2003).
  • Galzerano D, Tammaro P, Cerciello A et al. Freehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: a multicentre study. J. Hum. Hypertens.18, 53–59 (2004).
  • Freytag F, Schelling A, Meinicke T et al. Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study. Clin. Ther.23(1), 108–123 (2001).
  • Richter A, Gondek K, Ostrowski C et al. Mild-to-moderate uncomplicated hypertension: further analysis of a cost-effectiveness study of five drugs. Manag. Care Interface61–69 (2001).

Websites

  • World Health Report 2002: Reducing risks, promoting healthy life. Geneva, Switzerland: WHO, 2002 www.who.int/whr/2002
  • US Census Bureau www.census.gov (Accessed April 2007)
  • Boehringer Ingelheim International: Profess Study www.profess-study.com (Accessed April 2007)
  • Boehringer Ingelheim International: Prescribing Information for Micardis www.fda.gov (Accessed April 2007)
  • British National Formulary www.bnf.org (Accessed April 2007)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.